Algeria Gene Detection Technology Center



Image credit

We worked on a 25,000-words Simplified Chinese to English business proposal for the construction of a National gene detection technology application demonstration center in Algeria.

It consisted of a background study and statistical data of birth defects, genetic diseases leading to disabilities, and rising incidences of major illnesses in Algeria; contributing enormous strains to individual families and the society. It proposed that advances made in China and abroad in the biotechnology and genetics industry could help detect and treat illnesses by the 4P medical model – preventive medicine, predictive medicine, personalized medicine, and participatory medicine.


The proportion of newborn deafness in Algeria is around 1 % -3 %, and among more than 3,000 cases of newborn deafness each year, around 60% is caused by genetic factors. The incidence of Down syndrome is about 1/800-1/600, accounting for 70% -80% chance of occurrence in pediatric trichomes chromosome diseases, bringing serious economic strain to the community and causing enormous psychological pressure and mental stress on the family. At the same time, along with rapid economic and social development, incidences of cancer, cardiovascular disease, and other major diseases have shown a sharp upward trend.


Recent years has seen the international community highly valuing the progress made in the biotechnology and genetics industry, with special attention focused on expanding genetics testing technology to play a large-scale role in the screening of genetic diseases, cancer, and other major diseases, in individualized diagnosis and in other applications. A series of policies to support the industry in application development, prevention and treatment have been issued.


The genetic testing industry has gradually moved into a rapid development growth cycle. Within the genetics industry right now, genetic testing can be readily utilized with a broad range of applications, evolving into a business that can benefit human health. Since the complete implementation of the Human Genome Project (HGP) people’s understanding of genes has gradually deepened, genetic detection technology has rapidly developed, with the genetic testing industry chain gradually coming together. There are more and more genetic testing techniques moving from clinical research to clinically confirmed, mainly reflected in areas of disease risk prediction, assisting in the diagnosis of diseases, and providing guidance in health management and personalized care services.


In 1978, the famous Chinese American scientist Jane Yue Wei and colleagues used liquid-phase DNA molecular hybridization to successfully carry out genetic diagnosis on sickle cell anemia, marking the birth of genetic testing, resulting in a revolution in the field of disease diagnosis. In 1998, the United States officially launched the gene chip program, enabling quicker and easier gene screening. On June 22, 2000, the human genome plan sketch was completed. At the end of 2005, 454 Company launched the first high-throughput genome sequencing system based on the principle of pyrosequencing. In September 2013, Illumina’s MiseqDx platform passed the U.S. FDA’s technical certification for the first time as an open platform allowing capsule fibrosis reagent products to enter clinical use, marking the day that after 10 years of development, high-throughput sequencing technology has evolved from a pure science research platform into the field of clinical diagnosis.


With the development of gene detection technology in developed countries like Europe and America, the gene market has begun to take shape. Not only do a large number of professional companies provide genetic testing services, there are a few that develop gene repair drugs, research and develop, produce and sell genetic food.

随着基因技术和健康理念的发展,现代医学进入“4P”医学模式(4pmedicalmodel):1.预防医学(Preventive Medicine);2.预测医学(Predictive Medicine);3.个体医学(Personalized Medicine);4.参与医学(Participatory Medicine)。“4P”医学模式以解决慢性病问题为首要目标。

With the development of genetic technology and healthcare concepts, modern medicine enters a “4P” medical model (4pmedicalmodel): 1. Preventive Medicine; 2. Predictive Medicine; 3. Personalized Medicine; 4. Participatory Medicine. The “4P” Medical model aims to solve the problem of chronic diseases as its primary objective.


Preventive medicine involves multi-tiered actions: Foremost is people taking the initiative to prevent certain diseases through their own health habits; second tier is government policy intervention to encourage people taking proactive actions towards disease prevention through public policies, and making preventive medicine knowledge universal in order to improve the level of disease prevention across the community; the third tier is people choosing a green eco-city, embracing a low-carbon lifestyle through changing their environment.


The emergence of preventive medicine in the medical industry has seen “disease-cure” become an inevitable “macro health management” trend. In 2013, U.S. movie star Angelina Jolie had double mastectomy surgery performed to reduce her cancer risks after learning the results of her gene sequencing. Similar to her mother and aunt, she carried the BRCA1, BRCA2 gene, signifying she had a higher risk of developing ovarian cancer and breast cancer. To avoid this risk, Angelina had proactively made a preventive treatment, reducing her risk of developing breast cancer from 87% to 5%. This kind of preventive medicine based on genetic sequencing may very likely become a trend. In 2011, a survey of 1,463 respondents in the United States found that many people were willing to undergo predictive testing of diseases, with 76% of these 1,463 respondents willing to test for Alzheimer’s disease, breast cancer, prostate cancer, or arthritis. Respondents’ answers vary with the type, cost, and predictive accuracy of different diseases. The highest willingness was for prostate cancer (87%), followed by breast cancer (81%), and Alzheimer’s (72%).


Individualized diagnosis and treatment, gene detection, diagnosis, and treatment have entered the era of personalized medicine, using technology as the core disease diagnostic platform is the main direction of gene detection technology applications. The 2004 Nobel Prize winner Aaron Chernovo said that from now on we will enter a new “personalized medical” era. Future treatment options will be tailored to patient’s information. In recent years, individualized medicine, represented by gene sequencing, early screening of cancer and regenerative medicine, is ascending: In clinical practice, gene detection technology improves therapeutic results by detecting disease gene in diagnosis, clarifying the root cause, identifying drug-related gene markers, reducing medical costs; a 70-year-old Japanese female patient with exudative age-related macular degeneration underwent iPS cell transplantation, the surgery was the world’s first, marking it an important step forward using iPS cell in regenerative medicine.


With the improvement of people’s self-awareness and health concept in the modern society, more and more patients have evolved from passively allowing doctors decide their treatment methods, to taking a more proactive role to initiate and participate in the maintenance of their own health. Not only do these types of participation encourage patients to have more interaction with their doctors during the course of disease diagnosis and treatment, it also improves patients’ drug compliance, with the objective to improve people’s health management concept on the whole. People will gradually realize that fine, micro health management, such as temperature and blood glucose monitoring for women, etc., will improve their overall health condition and doctor’s visit experience. The way to a cure depends on the doctor, but not getting sick, a lot of times, depends on one’s own behavior and decisions.

We further worked on the technology and application for detections of the following diseases, the construction model of the center, and investment details. The content was meticulously researched to ensure its accuracy. Our client was happy with our efforts.


Molecular genetic disease detection, cancer molecular detection, cardiovascular and cerebrovascular diseases molecular detection, molecular detection of infectious and other diseases. Mainly providing genetic deafness gene detection, Down syndrome gene detection, neonatal genetic metabolic disease tandem mass spectrometry screening, chromosome karyotype analysis and FISH detection, chromosomal abnormalities detection, thalassemia detection, other single gene disease detection, hereditary cancer gene detection, tumor-related virus gene detection, plasma miRNA marker detection, breast cancer prognosis gene detection, leukemia fusion gene detection, multiple myeloma gene detection, individualized cancer drug detection, individualized cardiovascular and cerebrovascular disease drug detection, human papillomavirus (HPV) typing, hepatitis molecular diagnostics, detection of mycobacteria, other infectious diseases.

Large, technical translation. Nice work Bonnie – Ken, Los Angeles